Coenzyme Q₁₀ (CoQ) treatment monitoring is a matter of debate since CoQ distribution from plasma to blood cells and tissues is not fully understood. We aimed to analyze the CoQ levels in a wide set of human biological samples (plasma, blood mononuclear cells (BMCs), platelets, urinary cells, and skeletal muscle) from a group of 11 healthy male runners before and after CoQ supplementation. The CoQ content in the different samples was analyzed by HPLC coupled to electrochemical detection. No significant differences were observed in the CoQ levels measured in the BMCs, platelets, and urine after the one-month treatment period. Plasma CoQ (expressed in absolute values and values relative to total cholesterol) significantly increased after CoQ supplementation (p = 0.003 in both cases), and the increase in CoQ in muscle approached significance (p = 0.074). CoQ levels were increased in the plasma of all supplemented subjects, and muscle CoQ levels were increased in 8 out of 10 supplemented subjects. In conclusion, the analysis of CoQ in plasma samples seems to be the best surrogate biomarker for CoQ treatment monitoring. Moreover, oral CoQ administration was effective for increasing muscle CoQ concentrations in most subjects.

中文翻译：

---

不同人体生物样品中辅酶Q10处理的监测

辅酶Q ₁₀（CoQ）的治疗监测是一个有争议的问题，因为尚未完全了解从血浆到血细胞和组织的CoQ分布。我们旨在分析补充CoQ前后11名健康男性跑步者的一组人体生物学样本（血浆，血液单核细胞（BMC），血小板，泌尿细胞和骨骼肌）中的CoQ水平。通过HPLC结合电化学检测分析不同样品中的CoQ含量。治疗一个月后，在BMC，血小板和尿液中测得的辅酶Q水平无明显差异。补充辅酶Q后血浆辅酶Q（以绝对值和相对于总胆固醇的值表示）显着增加（p在两种情况下均= 0.003），并且肌肉中CoQ的增加接近显着性（p = 0.074）。在所有补充受试者的血浆中，辅酶Q水平均升高，在10名补充受试者中的8名中，肌肉辅酶Q水平升高。总之，血浆样品中辅酶Q的分析似乎是辅酶Q治疗监测的最佳替代生物标记。此外，口服辅酶Q可以有效地增加大多数受试者的肌肉辅酶Q浓度。